journal article·2024-02Open access

Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy

Xinxin Xie, Jinxia Zhang, Yuan Wang, Wanrui Shi, Rui Tang, Qingshuang Tang, Suhui Sun, Ruiqi Wu, Shuyu Xu, Mengxin Wang, Xiaolong Liang, Ligang Cui

Abstract

Immunotherapy as a milestone in cancer treatment has made great strides in the past decade, but it is still limited by low immune response rates and immune-related adverse events. Utilizing bioeffects of ultrasound to enhance tumor immunotherapy has attracted more and more attention, including sonothermal, sonomechanical, sonodynamic and sonopiezoelectric immunotherapy. Moreover, the emergence of nanomaterials has further improved the efficacy of ultrasound mediated immunotherapy. However, most of the summaries in this field are about a single aspect of the biological effects of ultrasound, which is not comprehensive and complete currently. This review proposes the recent progress of nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy. The concept of immunotherapy and the application of bioeffects of ultrasound in cancer immunotherapy are initially introduced. Then, according to different bioeffects of ultrasound, the representative paradigms of nanomaterial augmented sono-immunotherapy are described, and their mechanisms are discussed. Finally, the challenges and application prospects of nanomaterial augmented ultrasound mediated cancer immunotherapy are discussed in depth, hoping to pave the way for cancer immunotherapy and promote the clinical translation of ultrasound mediated cancer immunotherapy through the reasonable combination of nanomaterials augmented ultrasonic bioeffects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Treating tumors with minimally invasive therapy: a review
2. Minimally invasive nanomedicine: nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated therapy and imaging10.1039/D1CS01148K ↗
3. Gene expression profiles in normal and cancer cells10.1126/science.276.5316.1268 ↗
4. Biomaterial-based in situ cancer vaccines
5. Immune checkpoint inhibitors: recent progress and potential biomarkers10.1038/s12276-018-0191-1 ↗
6. Breakthrough of the year 2013, Cancer immunotherapy10.1126/science.342.6165.1432 ↗
7. Vaccine-like nanomedicine for cancer immunotherapy10.1016/j.jconrel.2023.02.015 ↗
8. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
9. The landscape of CAR-T cell clinical trials against solid tumors-A comprehensive overview10.3390/cancers12092567 ↗
10. Top 10 challenges in cancer immunotherapy10.1016/j.immuni.2019.12.011 ↗
11. Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles10.1038/s41467-022-31551-6 ↗
12. Ultrasound-mediated nano drug delivery for treating cancer: fundamental physics to future directions10.1016/j.jconrel.2023.02.009 ↗
13. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice10.1038/s41467-019-09760-3 ↗
14. Activating drugs with sound: mechanisms behind sonodynamic therapy and the role of nanomedicine10.1021/acs.bioconjchem.0c00029 ↗
15. The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine10.3390/molecules25010112 ↗
16. Advances in nanotechnology, nanopollution, nanotoxicology, and nanomedicine10.1007/s11356-020-08800-6 ↗
17. Ultrasound-augmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death10.1021/acs.nanolett.0c04778 ↗
18. Engineering the MoS(2)/MXene heterostructure for precise and noninvasive diagnosis of prostate cancer with clinical specimens10.1002/advs.202206494 ↗
19. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
20. Role of local radiation therapy in cancer immunotherapy10.1001/jamaoncol.2015.2756 ↗
21. Boussiotis, the complex role of tumor-infiltrating macrophages10.1038/s41590-022-01267-2 ↗
22. Tumor-associated human dendritic cell subsets: phenotype, functional orientation, and clinical relevance10.1002/eji.202149487 ↗
23. Hemostasis and tumor immunity10.1002/rth2.12728 ↗
24. ROS scavenging nanozyme modulates immunosuppression for sensitized cancer immunotherapy
25. Harnessing innate immunity in cancer therapy10.1038/s41586-019-1593-5 ↗
26. Harnessing innate immunity using biomaterials for cancer immunotherapy10.1002/adma.202007576 ↗
27. Innate immune cells and their contribution to T-cell-based immunotherapy10.3390/ijms21124441 ↗
28. Tumor-infiltrating B lymphocytes: promising immunotherapeutic targets for primary liver cancer treatment10.3390/cancers15072182 ↗
29. B lymphocytes and cancer: a love-hate relationship10.1016/j.trecan.2016.10.010 ↗
30. Jingjing He, Xinxin Xiong, Han Yang, Dandan Li, Xuefei Liu, Shuo Li, Shuangye Liao, Siyu Chen, Xizhi Wen, Kuai Yu, Lingyi Fu, Xingjun Dong, Kaiyu Zhu, Xiaojun Xia, Tiebang Kang, Chaochao Bian, Xiang Li, Haiping Liu,l Peirong Ding, Xiaoshi Zhang, Zhenjiang Liu, Wende Li, Zhixiang Zuo, Penghui Zhou, Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response, Cell Res.. 32(6) 530-542, https://doi:10.1038/s41422-022-00627-9..10.1038/s41422-022-00627-9 ↗
31. Therapeutic targeting of regulatory T cells in cancer10.1016/j.trecan.2022.06.008 ↗
32. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade10.1158/0008-5472.CAN-21-4141 ↗
33. Extracellular-vesicle-based drug delivery systems for enhanced antitumor therapies through modulating the cancer-immunity cycle
34. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle10.1016/j.apsb.2021.05.031 ↗
35. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy10.1038/nrc.2016.36 ↗
36. Neoadjuvant checkpoint blockade for cancer immunotherapy10.1126/science.aax0182 ↗
37. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
38. Next generation of immune checkpoint inhibitors and beyond10.1186/s13045-021-01056-8 ↗
39. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response10.1038/s41392-022-01136-2 ↗
40. Cellular networks controlling T cell persistence in adoptive cell therapy10.1038/s41577-021-00539-6 ↗
41. Principles of adoptive T cell therapy in cancer10.1007/s00281-018-0703-z ↗
42. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance10.1111/imr.12772 ↗
43. A guide to manufacturing CAR T cell therapies10.1016/j.copbio.2018.01.025 ↗
44. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials10.1002/ajh.26301 ↗
45. The journey of CAR-T therapy in hematological malignancies10.1186/s12943-022-01663-0 ↗
46. Tumor-infiltrating lymphocytes in the immunotherapy era10.1038/s41423-020-00565-9 ↗
47. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial10.1038/s41591-021-01462-y ↗
48. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma10.1172/JCI150535 ↗
49. Chesney · J Immunother Cancer · 2022 · 1010.1136/jitc-2022-005755 ↗
50. The anticancer potential of T cell receptor-engineered T cells10.1016/j.trecan.2020.09.002 ↗
51. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune response in patients with metastatic melanoma10.1158/1078-0432.CCR-20-1247 ↗
52. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma10.1002/ijc.34453 ↗
53. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases10.1016/j.anai.2019.04.015 ↗
54. Ultrasound microbubbles mediated sonosensitizer and antibody co-delivery for highly efficient synergistic therapy on HER2-positive gastric cancer10.1021/acsami.1c21924 ↗
55. Antibody-drug conjugates for cancer10.1016/S0140-6736(19)31774-X ↗
56. The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer10.1016/j.ctrv.2022.102500 ↗
57. ECHELON-1 study group, overall survival with Brentuximab vedotin in stage III or IV Hodgkin's lymphoma10.1056/NEJMoa2206125 ↗
58. Brentuximab vedotin with chemotherapy in pediatric high-risk hodgkin's lymphoma10.1056/NEJMoa2206660 ↗
59. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma10.1182/bloodadvances.2021005056 ↗
60. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study10.1111/bjh.16087 ↗
61. Bispecific antibodies in oncology10.1038/d41573-022-00040-2 ↗
62. Blinatumomab improves outcomes in infant ALL10.1038/s41571-023-00780-z ↗
63. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia10.1056/NEJMoa2214171 ↗
64. Vaccines as treatments for prostate cancer10.1038/s41585-023-00739-w ↗
65. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
66. Fueling immune checkpoint blockade with oncolytic viruses: current paradigms and challeges ahead10.1016/j.canlet.2022.215937 ↗
67. Oncolytic virotherapy: basic principles, recent advances and future directions10.1038/s41392-023-01407-6 ↗
68. Therapy with oncolytic viruses: progress and challenges10.1038/s41571-022-00719-w ↗
69. Harnessing cytokines and chemokines for cancer therapy10.1038/s41571-021-00588-9 ↗
70. Engineering interferons and interleukins for cancer immunotherapy10.1016/j.addr.2022.114112 ↗
71. Type I interferon-mediated tumor immunity and its role in immunotherapy10.1007/s00018-022-04219-z ↗
72. Cytokines in cancer immunotherapy10.1101/cshperspect.a028472 ↗
73. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs10.1073/pnas.1814446115 ↗
74. Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission10.1136/jitc-2020-001219 ↗
75. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade10.1016/j.cell.2022.01.008 ↗
76. Engineering enhanced CAR T-cells for improved cancer therapy10.1038/s43018-021-00241-5 ↗
77. Engineered T cell therapy for viral and non-viral epithelial cancers10.1016/j.ccell.2022.10.016 ↗
78. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies10.1016/j.jaci.2020.07.025 ↗
79. Cancer vaccines: building a bridge over troubled waters10.1016/j.cell.2022.06.035 ↗
80. When cancer vaccines go viral10.1158/1078-0432.CCR-19-1652 ↗
81. Recent Advances in nanomaterial-assisted combinational sonodynamic cancer therapy10.1002/adma.202003214 ↗
82. Micro/nanoparticle‐augmented sonodynamic therapy (SDT): breaking the depth shallow of photoactivation10.1002/adma.201602012 ↗
83. Nanoparticle-assisted ultrasound: a special focus on sonodynamic therapy against cancer10.1016/j.cej.2018.01.060 ↗
84. Mechanical bioeffects of ultrasound10.1146/annurev.bioeng.6.040803.140126 ↗
85. Drug Delivery by ultrasound-responsive nanocarriers for cancer treatment10.3390/pharmaceutics13081135 ↗
86. Multiphysics modeling of low-intensity pulsed ultrasound induced chemotherapeutic drug release from the surface of gold nanoparticles10.3390/cancers15020523 ↗
87. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging10.14366/usg.14034 ↗
88. Ultrasound-mediated drug delivery10.1111/odi.12501 ↗
89. Peptide ligand-mediated targeted drug delivery of nanomedicines10.1039/C8BM01340C ↗
90. Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis10.1126/sciadv.add3599 ↗
91. Nano-bio interactions in cancer: from therapeutics delivery to early detection10.1021/acs.accounts.0c00413 ↗
92. Nanomaterials: synthesis and applications in theranostics10.3390/nano11123228 ↗
93. Ultrasound activated vesicle of janus Au-MnO nanoparticles for promoted tumor penetration and sono-chemodynamic therapy of orthotopic liver cancer10.1002/anie.201912768 ↗
94. Activatable semiconducting polymer pro-nanomodulators for deep-tissue sono-immunotherapy of orthotopic pancreatic cancer10.1002/anie.202305200 ↗
95. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation10.1016/j.jconrel.2019.01.027 ↗
96. An apoptotic body‐based vehicle with navigation for photothermal‐immunotherapy by precise delivery and tumor microenvironment regulation10.1002/adfm.202212118 ↗
97. Tumor‐targeted nano‐adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity10.1002/VIW.20220067 ↗
98. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy10.1021/acsnano.8b07371 ↗
99. Neutrophil camouflaged stealth nanovehicle for photothermal-induced tumor immunotherapy by triggering pyroptosis10.1002/advs.202207456 ↗
100. Metal-free two-dimensional nanomaterial-mediated photothermal tumor therapy10.1016/j.smaim.2020.09.001 ↗